Clinical Trial

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary…

4 months ago

New Published Data Show Reproducibility and Utility of Perspectum’s MRI in Patients With Metabolic Liver Disease

WASHINGTON & OXFORD, England--(BUSINESS WIRE)--#Healthcare--Perspectum announced two research studies that were recently published, bringing hope to people with metabolic dysfunction-associated…

4 months ago

POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)

BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased…

4 months ago

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise…

4 months ago

Hyivy Health Secures $2M Seed to Unlock New Model for Treating Pelvic Pain

Pelvic health startup Hyivy Health poised to offer better solutions to the 300M patients with pelvic floor dysfunction causing chronic…

4 months ago

Humaneva Group Secures Major US Private Equity Investment to Accelerate Global Clinical Research Market Expansion

WARSAW, POLAND / ACCESSWIRE / September 27, 2024 / Humaneva Inc. has entered into a significant investment agreement with Viking…

4 months ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic painMIAMI, FL / ACCESSWIRE / September 27, 2024…

4 months ago

Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company…

4 months ago

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine)…

4 months ago